



ADVITECH ANNOUNCES HIGHLIGHTS AND FINANCIAL RESULTS FOR THIRD QUARTER 2007

FOR IMMEDIATE RELEASE

TSX VENTURE EXCHANGE: AVI

QUEBEC CITY, QUEBEC — November 29, 2007 — Advitech Inc. (“Advitech” or the “Company”) (TSX Venture Exchange: AVI) today announced its 2007 third quarter highlights and financial results.

During the third quarter of 2007, Advitech’s revenues from Dermylex™ sales have continued to increase and significant progress has been made to expand our products portfolio with the announcement of positive preclinical results in wound healing.

HIGHLIGHTS OF THIRD QUARTER

- Third quarter revenues reached \$377,000, a 38% increase over the previous 2007 quarter. The increase resulted from a 20% increase in Dermylex™ sales, and from non-recurring royalty revenue. Compared to the third quarter of 2006, revenues increased by 27%. The increase is mainly the result of Dermylex™ sales. The Company expects continued growth for the final quarter of 2007.
- Dermylex™ is now available in the U.S. under the BioDerm brand name, in France under the Psopax brand name and in Canada (Dermylex™). We plan to sign two additional marketing and distribution agreements in the fourth quarter of 2007.
- Positive preclinical results for a new wound healing application for XP-828L technology platform were announced. Wound healing is a large market. Biological wound-healing products generate, according to Kalorama Information, \$350 million in revenue worldwide, with a 27% annual growth rate for five years. An initial product release is planned during 2008.
- Advitech revealed new efficacy results from a post-marketing study that shows that using Dermylex™ with topical corticosteroids and vitamin D analogs can create a synergistic effect and improve overall treatment efficacy. The main study’s findings were the subject of a scientific publication in October.
- The Company granted Diversified Natural Products (DNP) an exclusive worldwide license for the development and commercialization of the IBD application of our XP-828L technology platform. We elected to focus our energy on derma related applications only.

FINANCIAL RESULTS

Third quarter ended September 30, 2007:

- Third quarter revenues reached \$377,000, a 38% increase over the previous 2007 quarter. The increase resulted from a 20% increase in Dermylex™ sales, and from non-recurring royalty revenue. Compared to the third quarter of 2006, revenues increased by 27%. The increase is mainly the result of Dermylex™ sales. The Company expects continued growth for the final quarter of 2007.
- Net loss was \$302,000, compared to \$266,000 for the third quarter of 2006, an increase of 13%, mostly driven by higher administrative expenses and by higher financial expenses related to the new financing.
- As at September 30, 2007, the Company had \$1.6 million cash on hand, compared to \$1.9 million as at June 30, 2007, a decrease of \$273,000 which results from third quarter operating activities.

Nine-month period ended September 30, 2007:

- Revenues increased by 51% to \$ 705,000 compared to \$ 465,000 for the corresponding period of 2006. The increase results from Dermylex™ sales growth arising from new American and French territories.
- Net loss was \$1,209,000 or \$0.02 per share, compared to \$987,000, or \$0.02 per share, for the corresponding period of 2006, an increase of 23% which is mainly the result of the cost related to the completion of the Company's funding plan and the research and development expenses related to the XP-828L technology platform development program.

“Financial and corporate results for the third quarter of 2007 are in line with the Company's plan and respect the guidelines of our business model” stated Mr. Renaud Beauchesne, CEO and President of Advitech Inc. He added that “revenue from sales of Dermylex™ is growing at a steady pace in accordance with our plan for fiscal 2007.”

“We are proud of the scientific goals reached through the quarter” stated Ms. Christina Juneau, Ph. D., Vice-President, Research and Development. “I am very excited about the preclinical results on wound healing. A new application in this field would open an access to an important market” added Ms. Juneau.

Selected financial information
(In thousands of dollars, except per share amounts)

	Three-month period ended September 30,		Nine-month period ended September 30,	
	2007 (Unaudited)	2006 (Unaudited)	2007 (Unaudited)	2006 (Unaudited)
Financial Results				
Total Revenues	\$ 377.5	\$ 298.1	\$ 704.6	\$ 465.3
Operating Expenses	\$ 679.5	\$ 564.5	\$ 1,914.0	\$ 1,452.5
Research and Development Costs, net of Tax Credits and Grants	\$ 85.4	\$ 103.9	\$ 333.8	\$ 299.3
Net Loss	\$ (302.0)	\$ (266.4)	\$ (1,209.4)	\$ (987.2)
Loss per Share, Basic and Diluted	\$ (0.00)	\$ (0.00)	\$ (0.02)	\$ (0.02)
			As at September 30, 2007 (Unaudited)	As at December 31, 2006 (Audited)
Balance Sheet				
Cash and Cash Equivalents			\$ 1,637.0	\$ 601.4
Other Current Assets			\$ 601.9	\$ 432.9
Long-term Assets			\$ 185.9	\$ 202.7
Current Liabilities			\$ 503.4	\$ 515.1
Long-term Liabilities			\$ 1,682.4	\$ 1,092.4
Shareholders' Equity			\$ 239.0	\$ (370.5)

The third quarter financial statements as well as the management's discussion and analysis of results of operations and financial condition, are available on Sedar: <http://www.sedar.com/>.

About Advitech Inc. www.advitech.com

Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of Immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease. Recently, Advitech launched Dermylex™ for the treatment of mild-to-moderate psoriasis.

About Dermylex™ www.dermylex.com

Dermylex™, developed by Advitech, is an oral natural health product formulated to improve mild-to-moderate psoriasis symptoms. Two clinical trials, including a 112-day, multi-center, double-blind, placebo-controlled trial with 84 patients, clinically proved the efficacy and safety of Dermylex™ for that type of psoriasis. Dermylex™ is currently available in Canada and the U.S. (as BioDerm, Dermylex), and will soon be available in France and Belgium (as Psopax).

-30-

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Advitech Inc.

Renaud Beaudesne, MBA
President and Chief Executive Officer
418-686-7498, ext. 228
info@advitech.com
www.advitech.com

Serge Comeau
Investor's relations
514-862-4160
s.comeau@advitech.com